Regulatory

Biovica Year-end Report for 2019/2020:

Preparations for the launch of DiviTum® have started

June 5, 2020

Biovica provides market share target at today’s Capital Market Day

Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica’s market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.

May 11, 2020

DiviTum – first study published on CDK4/6 inhibitor against clinical results

Period: May-January 2019/2020

March 12, 2020

Q2 Interim report: Work with the FDA application progressing as planned

“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world’s largest scientific conference on breast cancer”. – Anders Rylander, CEO of Biovica

December 5, 2019

Plan for 510(k) submission specified – Q1 Interim Report: May-July 2019/2020

SEK thousands  Q1 19/20  Q1 18/19  May-April 18/19  Net sales  367  914  3,005  Operating profit (loss)  -6,097  -3,956  -21,718  Profit (loss) for the period  -6,068  -4,028  -21,556  Earnings per share, after dilution  -0.33  -0.23  -1.18  Significant events during the first quarter  Targeted new share issue for SEK 60 million to European and Swedish institutional investors […]

August 29, 2019

FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)

SEK thousands Q4 18/19 Q4 17/18 May-April 18/19 May-April 17/18 Net sales 1,715 1,433 3,005 2,723 Operating profit (loss) -8,569 -4,132 -21,718 -17,956 Loss for the period -8,631 -4,176 -21,556 -18,010 Earnings per share, after dilution -0.47 -0.24 -1.18 -1.01

June 14, 2019

Announcement from Biovica’s extra general meeting

The extra general meeting (“EGM”) of Biovica International AB (publ) (“Biovica” or the “Company”) was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors’ resolution to issue new class B shares with deviation from the shareholders’ preferential rights

May 2, 2019

Notice of extra general meeting in Biovica International AB

The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Thursday 2 May 2019 at 13.00 pm CET at Baker & McKenzie's premises at Vasagatan 7 in Stockholm. The doors to the meeting will open at 12.45 pm CET. Right to attend and notification Shareholders […]

April 9, 2019

Interim Report May-January 2018/2019

Significant events during the third quarter · Abstract was presented at San Antonio Breast Cancer Symposium · New office and staff in USA Significant events after the end of the period · Abstract to be presented at AACR in April · Shares now traded on Nasdaq First North Premier · Lars Holmqvist elected as new Chairman · Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.

March 21, 2019

Report from Biovica’s Extra Shareholder’s Meeting on March 20, 2019

Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.

March 20, 2019